The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Integrating BCMA-targeted immunotherapies into challenging multiple myeloma cases
Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, University College London Hospitals, London, UK, provides an insight into the integration of BCMA-targeted immunotherapies into the treatment paradigm for subgroups of patients with challenging cases of multiple myeloma (MM), including elderly patients and those with rapidly proliferative disease. CAR T-cell therapy has limited utility due to the need for bridging therapy and the high risk of cytokine release syndrome (CRS). Dr Popat highlights that bispecific antibodies, particularly at lower-intensity dosing schedules, are a more tolerable treatment option for these patients. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
GSK: Consultancy, Honoraria, Research Funding; Janssen: Honoraria; BMS: Honoraria; AbbVie: Honoraria; Roche: Honoraria; University College London Hospitals NHS Foundation Trus: Current Employment. Gironella: Janssen: Consultancy, Honoraria; GSK: Consultancy.
